| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/11/2004 | US20040048867 Especially quinoline carbonyl pyrrolidines with binding selectivity to benzodiazepine site of GABAA receptor to treatanxiety, depression, a sleep disorder, or cognitive impairment. |
| 03/11/2004 | US20040048864 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| 03/11/2004 | US20040048863 Treating osteoarthritis or rheumatoid arthritis |
| 03/11/2004 | US20040048862 Chemical compounds |
| 03/11/2004 | US20040048861 Containing two nitrogen-heteroaromatic groups with hydrogen bonding |
| 03/11/2004 | US20040048860 Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| 03/11/2004 | US20040048859 Substituted glutarimides and their use as inhibitors of IL-12 production |
| 03/11/2004 | US20040048858 Chalcone derivatives and their use to treat diseases |
| 03/11/2004 | US20040048857 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. |
| 03/11/2004 | US20040048856 Monoamine reuptake inhibitors for treatment of CNS disorders |
| 03/11/2004 | US20040048853 Compounds, compositions, and methods |
| 03/11/2004 | US20040048852 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/11/2004 | US20040048851 Amidinophenylalanine derivatives as thrombin inhibitors |
| 03/11/2004 | US20040048850 Activators of soluble guanylate cyclase. |
| 03/11/2004 | US20040048849 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 03/11/2004 | US20040048848 Novel gamma secretase inhibitors |
| 03/11/2004 | US20040048847 Increasing the sugar-transporting capacity; preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis |
| 03/11/2004 | US20040048846 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 03/11/2004 | US20040048845 Containing indolecarbazole compounds, such as staurosporine. |
| 03/11/2004 | US20040048844 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 03/11/2004 | US20040048843 And aza- and diaza-derivatives thereof; especially treating allergy or nasal congestion |
| 03/11/2004 | US20040048842 Delivering a beam of pulsed or scanned radiation to induce selective photothermolysis of blood vessels disposed within the region, and to activate the photosensitizer that has been administered locally to the region |
| 03/11/2004 | US20040048841 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 03/11/2004 | US20040048840 Modulation of matrix metalloproteinase (MMP) activity with aldosterone blocker(s) |
| 03/11/2004 | US20040048839 Or metabolizable precursors thereof, such as Delta 5-androstene-3b- acetoxy-7,17-dione, used to treat autoimmune disorders |
| 03/11/2004 | US20040048837 Method for treatment of renal disease |
| 03/11/2004 | US20040048836 Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients |
| 03/11/2004 | US20040048835 7-Substituted fused ring tetracycline compounds |
| 03/11/2004 | US20040048834 Antitumoral compounds |
| 03/11/2004 | US20040048832 Compounds useful in preparing camptothecin derivatives |
| 03/11/2004 | US20040048830 Administering a cyclic oligosaccharide such as 6-per-deoxy-6-per-(2,3- dihydroxypropylthio)- gamma -cyclodextrin; treating depression and other psychological disorders such as Cushing's syndrome, schizophrenia and severe anxiety |
| 03/11/2004 | US20040048829 Molecular inclusion compounds |
| 03/11/2004 | US20040048828 Immunosuppressive agent and food |
| 03/11/2004 | US20040048827 Regulation of the expression of genes as beta -secretase, presenilin-1, presenilin-2 gamma -amyloid protein precursor. |
| 03/11/2004 | US20040048823 Induces apoptotic death of cancer cells and inhibitors of Rb protein expression, including an antisense Rb oligonucleotide, which sensitize cancer cells to mycolactone. |
| 03/11/2004 | US20040048820 Prevention or therapy of cardiovascular complications |
| 03/11/2004 | US20040048816 Restenosis treatment |
| 03/11/2004 | US20040048815 Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals |
| 03/11/2004 | US20040048814 Sustained release composition contraining clarithromycin |
| 03/11/2004 | US20040048813 A solution of a spinosyn including spinosad, spinosyn A, and/or spinosyn D |
| 03/11/2004 | US20040048812 Health supplement |
| 03/11/2004 | US20040048811 Drynaria extractions for treating osteoporosis and their extraction process |
| 03/11/2004 | US20040048809 Micronized digoxin, hydrophilic polymer(s) (e.g., hydroxypropyl methyl cellulose) and optional excipient(s) in the form of a tablet that releases not more than 50% digoxin in 5 minutes and at least 85% digoxin in 60 minutes. |
| 03/11/2004 | US20040048808 Administering oleouropein and/or the products of its hydrolysis; inhibiting the vascularization of endothelial cells; used to treat a wide variety of cancers, ocular diseases, and inflammatory conditions. |
| 03/11/2004 | US20040048807 Angiogenesis inhibitors |
| 03/11/2004 | US20040048805 Antilipemic agents |
| 03/11/2004 | US20040048804 Prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by use of hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| 03/11/2004 | US20040048803 Treatment of thrombosis by administering a CD154 inhibitor, especially a metalloproteinase inhibitor. |
| 03/11/2004 | US20040048802 Hepatitis C virus inhibitors |
| 03/11/2004 | US20040048799 Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
| 03/11/2004 | US20040048795 Stimulating a vagus nerve pathway in the brain; inhibiting apoptosis of a cardiac myocyte |
| 03/11/2004 | US20040048786 Antibiotic coating for porous bodies and method for its production as well as its use |
| 03/11/2004 | US20040048785 By fibroblasts and/or keratinocytes; particularly hyaluronic acid, and/or proteoglycans |
| 03/11/2004 | US20040048780 Administering an agent which inhibits protein kinase A phosphorylation of a type 2 ryanodine receptor (RyR2); for treating a subject afflicted with exercise-induced or stress-induced cardiac arrhythmia |
| 03/11/2004 | US20040048779 Use of rotigotine for treating the restless leg syndrome |
| 03/11/2004 | US20040048777 Compounds and compositions for delivering active agents |
| 03/11/2004 | US20040048776 Medicament for preventive and therapeutic treatment of fibrosis |
| 03/11/2004 | US20040048774 Inhibitors of IMPDH enzyme |
| 03/11/2004 | US20040048773 Use of an antagonist of leptin for the manufacture of a medicament for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia |
| 03/11/2004 | US20040048772 Preventives for arthritis |
| 03/11/2004 | US20040048754 Capable of releasing perfumery, flavor, insect repellent or attractant, bactericide or fungicides |
| 03/11/2004 | US20040048390 Such as Sialyl Lewis X to detect cancer, or glucose in a sample; use in implantable sensor; compounds are anthracene-containing symmetrical diboronic acids |
| 03/11/2004 | US20040048369 Control of inward-rectifier K+ ion channels |
| 03/11/2004 | US20040048338 IL-17 receptor like molecules and uses thereof |
| 03/11/2004 | US20040048325 Glycosyltransferase inhibitors |
| 03/11/2004 | US20040048316 Comprises phosphorescence and fluorescence resonance energy transfer; binding chenodeoxycholic acid to farnesoid X receptors; for regulating cholesterol absorption; for treatment of obesity |
| 03/11/2004 | US20040048293 Useful for obtaining tumour-selective gene expression in tumours having a mutated beta -catenin pathway; used to express genes encoding therapeutic proteins in colorectal cancer cells |
| 03/11/2004 | US20040048280 A polynucleotide that includes an endothelial specific enhancer element |
| 03/11/2004 | US20040048266 Regulation of human membrane-type serine protease |
| 03/11/2004 | US20040048254 Isolated nucleic acid of given sequence; oligomer which hybridizes to a chemically pretreated DNA; detecting the cytosine methylation state |
| 03/11/2004 | US20040047971 Process for the preparation of a fat composition containing sterol esters a product obtained by said process and the use thereof |
| 03/11/2004 | US20040047969 Phytosterol compositions |
| 03/11/2004 | US20040047955 Color-enhanced food product |
| 03/11/2004 | US20040047948 Nutrients |
| 03/11/2004 | US20040047922 Prevents the development of atherosclerosis |
| 03/11/2004 | US20040047921 Useful for restoring or maintaining colon functionality in a human; prophylaxis of cancer |
| 03/11/2004 | US20040047919 Methods and compositions involving aldose reductase inhibitors |
| 03/11/2004 | US20040047918 Napthalamide compositions and uses thereof |
| 03/11/2004 | US20040047917 Drug delivery and targeting with vitamin B12 conjugates |
| 03/11/2004 | US20040047916 Compositions and methods for the treatme of primary and metastatic neoplastic disea using arsenic compounds |
| 03/11/2004 | US20040047908 For inducing or maintaining sleep |
| 03/11/2004 | US20040047907 Controlled release hydrocodone formulations |
| 03/11/2004 | US20040047906 Dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion; chronotherapy for cardiovascular diseases |
| 03/11/2004 | US20040047904 Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
| 03/11/2004 | US20040047903 For use in therapy of cancer |
| 03/11/2004 | US20040047898 Administering to cat or dog, an amount of Vitamin E sufficient to increase the plasma vitamin E level |
| 03/11/2004 | US20040047896 Composition for improving age-related physiological deficits and increasing longevity |
| 03/11/2004 | US20040047894 Preparation for improved dietary utilisation |
| 03/11/2004 | US20040047893 Method for preventing crystal formation in a dispersion of a liquid in a matrix |
| 03/11/2004 | US20040047885 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 03/11/2004 | US20040047878 DNA vaccine against feline immunodeficiency virus |
| 03/11/2004 | US20040047876 Compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress proteins |
| 03/11/2004 | US20040047874 Inhibition of antigen presentation with poorly catabolized polymers |
| 03/11/2004 | US20040047863 Administering TNF(Tumor necrosis factor) binding protein and at least one additional anti-inflammatory drug, for therapy of an acute or chronic inflammatory disease |
| 03/11/2004 | US20040047856 Colorstrum-based composition |
| 03/11/2004 | US20040047852 Method of treating cancer |
| 03/11/2004 | US20040047851 Treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingomyelinase inhibitors effective to decrease |
| 03/11/2004 | US20040047850 Bifidobacteria and preparations containing them |
| 03/11/2004 | US20040047845 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 03/11/2004 | US20040047844 Methods and processes of inactivating viral contaminants in a biological source material (e.g. a host cell, cell supernatant, cell lysate, blood plasma, tissue homogenate, or other biological materials) with a solution containing |